Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81.96 indicates a potential upside of 62.8%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.57. While the lowest estimate of $30 indicates a 40.4% decline from the ...